SARTATE Neuroblastoma trial advances to cohort 2
Filed with ASX · · 2 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Managing Directors Presentation to Annual General Meeting
- Quarterly Activity Report
- Dosimetry Recruitment of theranostic prostate trial complete
- Appendix 4C Cash Flow Report
- Recruitment closed on C-BOBCAT SAR-Bombesin trial
Later from Clarity Pharmaceuticals
- Clarity receives $3.26 million R&D tax incentive refund
- US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA
- First patient treated in cohort 2 neuroblastoma trial
- Update on China Grand Pharmaceutical and Healthcare Holdings
- Half Year Accounts
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals